natgillin/translations-raw huggingface dataset:
Optionally, compounds of the present invention can be used alone, in combination with other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-obesity agents; anti-diabetic agents, appetite suppressants; cholesterol/lipid-lowering agents, HDL-raising agents, cognition enhancing agents, agents used to treat neurodegeneration, agents used to treat respiratory conditions, agents used to treat bowel disorders, anti-inflammatory agents; anti-anxiety agents; anti-depressants; anti-hypertensive agents; cardiac glycosides; and anti-tumor agents. 
Opcijski, spojevi prikazanog izuma mogu se upotrijebiti samostalno, u kombinaciji sa drugim prikladnim terapeutskim agensima koji su korisni u liječenju prije spomenutih poremećaja uključujući: sredstva protiv gojaznosti, sredstva protiv dijabetesa, sredstva za potiskivanje apetita, sredstva za snižavanje kolesterola/lipida, sredstva za povišenje HDL, sredstva za ubrzavanje kognitivnih sposobnosti, sredstva koja se upotrebljavaju za neurodegeneraciju, sredstva koja se upotrebljavaju za liječenje dišnih stanja, sredstva koja se upotrebljavaju za liječenje oboljenja crijeva, protuupalna sredstva, sredstva protiv anksioznosti, antidepresive, sredstva za snižavanje krvnog tlaka, srčane glikozide i sredstva protiv tumora.
The process of claim 1 wherein in the compound of formula (VI) R′ is tri (C1-C3 alkyl)silyl and R is C1-C4 alkoxycarbonyl or benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from the group consisting of halogen, cyano, trifluoromethyl. The process of claim 4 wherein R is tert-butoxycarbonyl. 
Postupak iz patentnog zahtjeva 7, naznačen time da u spoju formule (VI) R' jest tri(C;-C; alkil)silil, a R jest C;-C alkoksikarbonil ili benziloksikarbonil koji je na aromatskom prstenu supstituiran s do tri supstituenta odbranih od sljedećih: halogen, cijano 1 trifluometilna skupina.
continuous infusion or bolus). 
kontinuirana infuzija ili u bolusu).
Ulipristal acetate, or any metabolite thereof, for use in treating or preventing a tumour derived from leiomyomata according to anyone of claims 1 to 12, wherein said patient suffers from uterine fibroids and said ulipristal acetate, or said metabolite thereof, is further for use for reducing or stopping bleedings or for reducing the size of uterine fibroids in said patient. 
Ulipristal acetat (17a-acetoksi-11B-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice.
Pharmaceutical composition according to claim 3, comprising a mixture of at least 2 compounds according to formulae II, III, IV and/or V,and/or salts, derivatives and/or stereoisomers thereof. 
Farmaceutski pripravak u skladu s prethodnim patentnim zahtjevom, naznačen time što sadrži smjesu najmanje 2 spoja formula II, IIL, IV i/ili V, i/ili njihovih soli.
wherein Z is CH2, CH—R10, O, S, N—R10; t is an integer equal to 1 or 2; and the dotted line represents an optional bond; is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; 
Het ili radikala formule pri čemu Z je CH,, CH-R'", O, S, N-R!" tje cijeli broj jednak 1 ili 2; i isprekidana crta predstavlja vezu po izboru;
More preferably, the density of the cured extended release matrix formulation in comparison to the density of the uncured extended release matrix formulation decreases by at least about 0.7%, at least about 0.8%, at least about 1.0%, at least about 2.0% or at least about 2.5%. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da, formulacija matrice s produljenim otpuštanjem ima snagu pucanja od barem oko 120 N, od barem oko 130 N ili od barem oko 140 N i/ili,,dubinu prodiranja s razmakom pukotine" od barem oko 1.2 mm, poželjno od barem oko 1.4 mm, od barem oko 1.5 mm ili od barem oko 1.6 mm.
The present invention has a further important advantage that it is easily installed on existing boats that are equipped with electronic controls, and does not require that the boats themselves be modified, other than by connecting the receiver to the electronic controls. 
Opisani izum i daljnju važnu prednost da se može s lakoćom ugraditi na postojeća plovila koja su opremljena elektronskim kontrolama, i ne zahtijeva da sama plovila budu izmijenjena, osim spajanja prijemnika na elektronske kontrole.
In particular, any corrugation of the adhesion areas can be avoided, and the cell structure of the wood is less damaged, whereby an open cell structure results which is particularly well suited to accept the adhesive to be applied so that a glue practically invisible joint results. 
Naročito se može izbjeći bilo kakva hrapavost u predjelu koji se treba zalijepiti, i struktura stanica drva se manje oštećuje, pri čemu je otvorena struktura stanice naročito povoljna za prihvaćanje ljepila koje se treba nanijeti, tako da se dobiva praktički nevidljiv spoj.
Glass door panel (2) of a swing door for closing off an opening between two spaces, comprising a locking system (1) in order to lock the panel (2) in the event of fire, characterized in that the locking system (1) is a locking system according to one of the preceding claims. 
. za zabravljivanje (1), namijenjen zabravljivanju panela (2) u slučaju požara, naznačen time što je sustav za zabravljivanje (1) sustav za zabravljivanje u skladu s bilo kojim od prethodnih patentnih zahtjeva.
with aryl sulfonyl chloride derivatives, in presence of suitable solvent at ambient temperature to obtain a compound of formula (I), wherein all substitutions are as defined in claim 1 . 
(TED) sa derivatima aril sulfonil klorida, u prisutnosti pogodnog otapala kod temperature okoline da se dobije spoj sa formulom (1), pri čemu su sve supstitucije kako je definirano u zahtjevu 1.
ii) enveloping the inner core with the outer layer. 
HR P20190326 T1 ii) -obavijanje unutarnje jezgre vanjskim slojem.
The compound of claim 1 selected from the group consisting of: 
Spoj izabran iz grupe koju čine: [image]
said rotating shaft (5) is received in the through receptacle of the rotating support (3) while creating a form fit therewith with mating sections. 
- - ta rotirajuća osovina (5) ulazi u prolaz okretne potpore (3) pri čemu njihovi oblici međusobno odgovaraju i zahvaćaju se.
A liquefied gas treatment system for a vessel, which includes a cargo tank storing liquefied natural gas, and an engine using the liquefied natural gas stored in the cargo tank as fuel, the liquefied gas treatment system comprising: 
Sustav za obradu ukapljenog plina za plovilo, koje sadrži skladišni spremnik (11) za skladištenje ukapljenog zemnog plina, te motor (3) koji upotrebljava ukapljeni zemni plin uskladišten u skladišnom spremniku kao gorivo, naznačen time što sustav za obradu ukapljenog plina sadrži:
Four isoforms of IL-18BP generated by alternative mRNA splicing have been identified in humans so far. 
Četiri izooblika proteina IL-18BP nastaju alternativnim procesiranjem mRNA u ljudi.
No. 4,649,057); the combination of a food acid, and edible reducing agent and a carbohydrate thickener followed by freezing (U.S. Pat No. 4,751,091); a denatured proteinaceous solution of soybeans, wheat and corn (U.S. Pat. No. 5,128,159); simultaneously scrubbing and drenching with a liquid containing fungicide (U.S. Pat. No. 5,148,738); a slurry consisting of by products of the produce and certain sugars and acids (U.S. Pat. 
4,649,057); kombiniranje hranjive kiseline, jestivog reducirajućeg sredstva i ugljikovodičnog sredstva za zgušnjavanje, nakon čega slijedi zamrzavanje (US Pat. br. 4,751,091); denaturirana proteinska otopina soje, pšenice i kukuruza (US Pat. br. 5,128,159); istovremeno ispiranje i kvašenje tekućinom koja sadrži fungicid (US Pat. br. 5,148,738); suspenzija netopljivih čestica koja se sastoji od nusprodukata glavnog proizvoda i određenih šećera i kiselina (US Pat. br.
converting the compound of Formula LI to a compound of Formula LII; and 
konverziju spoja Formule LI u spoj Formule LII; i [image]
Use of a composition according to claim 1 for the manufacture of a medicament for the treatment or prevention of a deficiency of GLP-1. The use of claim 53, wherein the composition is a dosage form of the composition according to any one of claims 26 to 30. The method of claim 33 wherein said dosage form is provided as a combined preparation for simultaneous, separate or sequential use. 
Uporaba pripravka u skladu sa zahtjevom 1, naznačena time, da se koristi za izradu lijeka za liječenje ili prevenciju nedostatka GLP-1, Uporaba u skladu sa zahtjevom 50, naznačena time, da se koristi pripravak koji je dozirni oblik pripravka u skladu s bilo kojim zahtjevom 24 do 28.
Placing said plurality of plastic cards on the support wedge such that a second side of said plastic cards is opposite the engraver. 
stavljanja navedenih više plastičnih karata na nosivi klin, na takav način da je druga strana navedenih plastičnih karata nasuprot gravirki;
wherein said at least one peptide is coupled or fused to a pharmaceutically acceptable carrier. 
BR. 60), pri čemu je taj najmanje jedan peptid spojen ili staljen na farmaceutski prihvatljivi nosač.
A medicament comprising a compound represented by the formula (I) wherein R1 is as defined in claim 1, or a salt thereof, in combination with a calcium antagonist for the prophylaxis or treatment of nerve degeneration diseases. 
JA gdje R! je kao definiran u zahtjevu 1, ili njegovu sol, u kombinaciji s antagonistom kalcija za profilaksu ili liječenje degenerativnih oboljenja živaca, Lijek, naznačen time, da sadrži spoj prikazan formulom (1)
circuitry adapted to detect a first phase relation between the wiring phase at the reference location and the wiring phase at a relay location; 
- <krug (TM) za otkrivanje prvog faznog odnosa između faze vodiča na referentnoj lokaciji (1) i faze vodiča na relejnoj lokaciji (2); i
In another embodiment, wherein the curing time is measured according to method 2, the curing temperature is defined to be the target exhaust air temperature and the starting point of the curing step is defined to be the point in time when the exhaust air temperature reaches the curing temperature. 
Postupak prema zahtjevu 16, naznačen time da temperaturni profil u toku koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura barem oko 72 "€ i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 15 minuta do oko 2 sata.
wherein, when Ar2 is A2b), R6a is the same as that defined in claim 8 when Ar2 is A2b); when Ar2 is A1a) or A7c), R8 is the same as that defined in claim 4 when Ar2 is A1) or A7); 
o A gdje, kada Ar" je A2b), R je isto kao što je definirano u patentnom zahtjevu 8 kada Ar" je A2b); kada Ar" je Ala) ili A7c), R* je isto kao što je definirano u patentnom zahtjevu 4 kada Ar? je A1) ili A7);
A compound of formula (1) or a pharmaceutically acceptable salt or a solvate thereof, or a stereoisomeric form thereof, wherein R is hydrogen or C1-6alkyl; 
Spoj prema formuli (1) [image] ili njegova farmaceutski prihvatljiva sol ili njegov solvat ili njegov stereoizomerni oblik, naznačen time da R je vodik ili C1-6alkil;
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkylsulfonyl, perfluoroC1-4alkyl, diC1-4alkylamino, hydroxyl, and phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C1-4alkyl and perfluoroC1-4alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C1-4alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C3-8cycloalkyl; or C5-7cycloalkenyl; 
R' je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, Caalkil, Cyaalkiloksi, Cysalkilsulfonil, perfluoroC,alkil, diCiaalkilamino, hidroksil, i fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, Ciualkil 1 perfluoroC,aalkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i Ciaalkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; Cz_gcikloalkil; ili Cs»cikloalkenil;
A process according to claim 4 or 5 wherein the reduction step is carried out by catalytic hydrogenation. 
Postupak u skladu sa zahtjevom 4 ili 5, naznačen time, da se korak redukcije provodi katalitičkim hidriranjem.
An inhaler according to claim 2 or 3, wherein the piercing member (9,75) comprises at least two discrete piercing heads operable to pierce a corresponding number of holes in a blister aligned with the blister piercing member (9,75). 
Inhalator prema zahtjevu 2 ili 3, gdje dio za bušenje (9,75) obuhvaća barem dvije zasebne glave za bušenje kojo mogu probušiti odgovarajući broj rupica u blisteru koji je u ravnini s dijelom za bušenje blistera (9,75).
to 150 mg fish oil comprising 15 to 25 wt% of the fish oil eicosapentaenoic acid and 7 to 15 wt % of the fish oil docosahexanoic acid; 
- 1do 150 mgribljeg ulja koje sadrži 15 do 25 mas. % eikozapentaenske kiseline iz ribljeg ulja i 7 do 15 mas. % dokosaheksanske kiseline iz ribljeg ulja;
The method of claim 9, wherein in steps 2) and 3), the working gas and the carrier gas are air and/or oxygen and/or vapor; and the vapor is originated from the recycling of sensible heat of syngas. 
Postupak prema zahtjevu 9, naznačen time da u koracima 2) i 3), radni plin i plin nosač su zrak i/ili kisik i/ili para; i para potječe od recikliranja osjetne topline visoko temperaturnog sintetskog plina.
The method of claim 1 wherein the furnace is a glass furnace. 
Metoda iz patentnog zahtjeva 1 gdje je ložište stakleno ložište.
Process according to claim 8, wherein the amine of formula Z is reacted with a compound of formula I wherein R is (C1-C12)alkyl, wherein the amine of formula Z is preferably used in an amount of 1 to 5 equivalents. 
Postupak prema zahtjevu 8, naznačen time, da amin formule Z reagira sa spojem formule I, gdje R je (Ci-C12) alkil, pri čemu se amin formule Z poželjno upotrebljava u količini od 1 do 5 ekvivalenata.
The cooled granulation is then passed through a #12 screen. 
Nakon toga, ohlađena granulacija je provedena kroz sito veličine otvora 12.
This apparatus constitutes an integrated dispensing device comprising a housing with a lid, sealing means, a pressure source, a cooling device and a dispensing tap. 
Taj aparat predstavlja integrirani uređaj za točenje, koji obuhvaća kućište s poklopcem, sredstvo za brtvljenje, izvor pritiska, rashladni uređaj i pipac za točenje.
The title compound was obtained (m=3.06 g) in a 77% yield. 
Spoj iz naslova (m = 3,06 g) se dobije s prinosom od 77 %.
Alternatively, starting materials of formula II were prepared by reaction of suitably substituted N-protected 4-amino benzoic acids by chlorination of the carboxylic acid, and coupling with suitably substituted 2-amino thiazoles, under the same conditions as described above, followed by deprotection of the amino functionality under suitable conditions, such as acidolysis. 
Alternativno, početni materijali naznačen formulom III se dobivaju reakcijom prikladne supstituirane N-zaštićene 4-amino benzojeve kiseline sa kloriranjem karboksilne kiseline, i vezanjem sa prikladnim supstituiranim 2-amino tiazolima, pri istim uvjetima kao što su ranije opisani, praćeno s deprotekcijom funkcionalnosti amina pri prikladnim uvjetima, kao što je acidoliza.
Rapamycin at the 1 µg/ml dose induced platelet aggregation by approximately 20% after 8 minutes. 
Rapamicin u dozi od 1 ug/mL inducira agregaciju trombocita za približno 20% nakon 8 minuta.
The reaction mixture was stirred at room temperature for 24h, then the solvent was evaporated and the residue was re-dissolved in ethyl acetate (200 mL) and extracted with HCl (0.1M) x2, Na2CO3 (aq., sat.) 
Reakcijska smjesa se miješa pri sobnoj temperaturi kroz 24 sata, potom se otapalo otpari i ostatak se ponovno otopi u etil acetatu (200 ml) i ekstrahira sa HCI (0.1 M) x 2, NaCO; (vod., zas.)
calculating (54) from said varying torque and said obtained rotational top end drive speed an estimated torque-speed transfer function; 
- izračunavanja (54) procijenjene funkcije prijenosa okretnog momenta u brzinu iz navedenog promjenjivog okretnog momenta i navedene dobivene vršne brzine vrtnje pogona;
The method of aspect 11, further comprising packaging the thawed sample in an insulated packaging assembly. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što dodatno uključuje pakiranje odmrznutog uzorka slogu izoliranog pakiranja.
Example disorders of the central nervous system include depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension. 
Spoj u skladu s bilo kojim zahtjevom 1 do 11, naznačen time, da se koristi u postupku liječenja depresije, atipične depresije, bipolarnog poremećaja, anksioznosti, opsesivno-kompulsivnog poremećaja, socijalne fobije ili stanja panike, poremećaja spavanja, seksualne disfunkcije, psihoza, šizofrenije, migrene ili stanja povezanih s glavoboljom ili ostalom boli, povećanog intakranijalnog tlaka, epilepsije, poremećaja osobnosti, poremećaja ponašanja povezanih sa dobi, poremećaja ponašanja povezanih sa demencijom, organskih mentalnih poremećaja, mentalnih poremećaja u djetinjstvu, agresivnosti, poremećaja pamćenja povezanih s dobi, sindroma kroničnog umora, odvikavanja od droga ili alkohola, debljine, bulimije, anoreksije nervoze ili predmenstrualne napetosti.
The formulation of claim 2, wherein the neutralizing agent is triethanolamine, which is preferably present in an amount of 0.35%wt. 
Formulacija prema zahtjevu 2, naznačena time, da navedeno sredstvo za neutraliziranje je trietanolamin, koji je poželjno prisutan u količini od 0.35% tež.
The method of any one of claims 1 to 14, wherein the (±)-A9-tetrahydrocannabinol comprises at least 95%, preferably at least 98%, more preferably at least 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema bilo kojem od zahtjeva 7 do 10, naznačen time da (±)-A9-tetrahidrokanabinol sadrži barem 95% težinski, poželjno barem 98% težinski i poželjnije barem 99% težinski trans-(-)-A9-tetrahidrokanabinola i trans-(+)-A9-tetrahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
A pharmaceutical composition comprising the alkaline phosphatase of any one of claims 1 to 10 and a pharmaceutically acceptable carrier, preferably wherein the pharmaceutically acceptable carrier is a saline, more preferably wherein the alkaline phosphatase is in a lyophilized form. 
Farmaceutski pripravak naznačen time da sadrži alkalnu fosfatazu prema bilo kojem zahtjevu od 1 do 101i farmaceutski prihvatljiv nosač, pri čemu poželjno farmaceutski prihvatljiv nosač je fiziološka otopina, te poželjnije pri čemu je alkalna fosfataza u liofiliziranom obliku.
The housing 10 has an outer surface 10 a and an inner surface 10 b. 
- < kućište (10), koje ima vanjsku površinu (10a),
The method according to claim 1, wherein following addition of 2-aminoethanol to the suspension, the suspension is introduced in a container or unit up to a level determined by measurement of the suspension conductivity. 
Uporaba prema zahtjevu 16, naznačena time što se nakon dodavanja 2-aminoetanola suspenziji, ta suspenzija uvodi u spremnik ili jedinicu do razine utvrđene mjerenjem provodljivosti suspenzije.
The box appears in the shape of a rectangular prism and has a hinged lid. 
Kutija je u obliku pravokutne prizme i ima preklopni poklopac.
The composition of claim 1, wherein said composition is a coating of a coated solid oral formulation. 
Obložena čvrsta oralna formulacija u skladu s patentnim zahtjevima 20 do 22, naznačena time što je želučano otporna.
A compound represented by the formula (III): wherein R2 represents a hydrogen atom, or a linear, cyclic or branched alkyl group having 1 to 8 carbon atoms, 
Spoj predstavljen formulom (III): tia naznačen time što R> predstavlja vodikov atom, ili ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma,
A VZV gE antigen truncated to remove the C-terminal anchor region in combination with an adjuvant comprising 3D-MPL, QS21 and liposomes comprising cholesterol for use as a medicament for concomitant or sequential administration with a live attenuated VZV for preventing or decreasing the severity of herpes zoster and/or post herpetic neuralgia in individuals at risk from such diseases. 
VZV gE, C-terminalno skraćen kako bi se uklonilo karboksiterminalno sidrišno područje, te koji nije u obliku fuzijskog proteina, naznačen time što je namijenjen upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije u populaciji osoba starijih od 50 i imunosno oslabljenih osoba, gdje se VZV gE primijenjuje u kombinaciji s adjuvansom TH-1, koji sadrži QS21 i 3D-MPL.
On the 3rd day after observing no difficulties, the physician removes her BTDS 5 and replaces it with BTDS 10 for 3 days while decreasing her methadone by 25%. 
Na treći dan nakon što se utvrdi da ne dolazi do komplikacija, liječnik uklanja njen TSB 5 i zamjenjuje ga s TSB 10 kroz tri dana dok u isto vrijeme snizuje metadon za 25%.
Formula II 
Formula II pri čemu
In a further embodiment the invention also relates to use of a compound of the invention as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of post traumatic stress disorder. 
U jednom daljnjem obliku izum se također odnosi na korištenje spoja izuma kao slobodne baze ili njezine soli za pripravak farmaceutskog sastava kod za liječenje opsesivno-kompulzivnih smetnji.
the New Methylene Blue is present in amounts sufficient to result in concentrations of about 70 µM to about 2.4 mM under staining conditions; and 
Novo metilensko modrilo je prisutno u dovoljnoj količini da se dobiju koncentracije od oko 70 uM do oko 2.4 MM u uvjetima bojenja; i
initiation of T cell activation, such as provided by CD3 Z cytoplasmic domain T cell mediated cytotoxicity, 
započinjanje T ćelijske aktivacije, kao što je osigurano od strane CD3 Ć citoplazmatske domene - > T stanično posredovamu citotoksičnost, -
a step d1) for scrubbing with water and for fractionating said synthesis gas into at least two effluents: a first portion and a complementary portion, 
* korak d1) ispiranja s vodom i frakcioniranja navedenog sintetskog plina u barem dva efluenta: prvi dio i komplementarni dio,
A powdery composition comprising a steroidal molecule; and a pharmaceutically acceptable carrier having a specific surface area greater than 200 m2/g and at the most 1000 m2/g; wherein the steroidal molecule is dissolved in a solvent absorbed onto the surface of the pharmaceutically acceptable carrier and wherein the steroidal molecule is present in the solvent In a supersaturated concentration. 
HR P20090614 TI PATENTNI ZAHTJEVI Praškasti kompozit, naznačen time, da sadrži steroidnu molekulu; i amorfni silicijev dioksid koji ima specifičnu površinu od najmanje 250 m'/g; gdje je steroidna molekula otopljena u otapalu apsorbiranom na površinu amorfnog silicijevog dioksida i gdje je steroidna molekula prisutna u otapalu u superzasičenoj koncentraciji.